Perioperative Management of Colorectal Cancer Patients Infected With COVID-19: a Multicenter Prospective Cohort Study.
- Conditions
- Colorectal CancerSurgical Procedure, Unspecified
- Registration Number
- NCT05682898
- Lead Sponsor
- Changhai Hospital
- Brief Summary
This trial is a multicenter prospective cohort study to explore timing of colorectal cancer surgery after COVID-19 infection so that can assist clinicians and patients. Currently, there is less evidence on perioperative outcomes after COVID-19 vaccination and the omicron variant. Therefore, it is necessary to update previously published consensus which recommends that patients should avoid elective surgery within 7 weeks of COVID-19 infection remain, unless the benefits of doing so exceed the risk of waiting. Aiming at the above problems, we plan to carry out a multicenter prospective cohort study to develop perioperative management according patients' different conditions.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 300
- undergoing colorectal cancer surgery
- infected with COVID-19 but nucleic acid test result is negative
- the patients compliance is good
- signed the consents voluntarily
- undergoing emergency surgery(intestinal obstruction, intestinal perforation, intestinal hemorrhage, et al.)
- The patients' situations which judged by situations is not suitable to participate in the clinical trial
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of surgical complications 30 days after surgery Complications including: intraperitoneal hemorrhage, anastomotic leak, anastomotic bleeding, abdominal infection, pulmonary infection, chylous fistula, intestinal obstruction, et al.
- Secondary Outcome Measures
Name Time Method